Generalization testing with atypical and typical antipsychotic drugs in rats trained to discriminate 5.0 mg/kg clozapine from vehicle in a two-choice drug discrimination task

Drug Development Research

Volumn 64, Issue 1, 2005, Pages 55-65

  Prus, Adam J ^a   Philibin, Scott D ^a   Pehrson, Alan L ^a   Stephens, Chad L ^a   Cooper, Rhiannon N ^a   Wise, Laura E ^a   Porter, Joseph H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Antipsychotic; Chlorpromazine; Clozapine; Drug discrimination; Fluphenazine; Haloperidol; Olanzapine; Rats; Risperidone; Sertindole; Thioridazine; Ziprasidone

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; DRUG VEHICLE; FLUPHENAZINE; HALOPERIDOL; LACTIC ACID; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; UNCLASSIFIED DRUG; WATER; ZIPRASIDONE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEIONIZED WATER; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG DISCRIMINATION; DRUG SELECTIVITY; DRUG SUBSTITUTION; MALE; NONHUMAN; RAT; TASK PERFORMANCE; TRAINING;

EID: 18044376991     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10419     Document Type: Article

References (50)

1. Arnt J, Skarsfeldt T. 1998. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63-101.
2. Bruhwyler J, Liegeois JF, Bergman J, Carey G, Goudie A, Taylor A, Meltzer H, Delarge J, Geczy J. 1997. JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity: a review of its behavioural properties. Pharmacol Res 36:255-264.
3. Carey GJ, Bergman J. 1997. Discriminative-stimulus effects of clozapine in squirrel monkeys: comparison with conventional and novel antipsychotic drugs. Psychopharmacology 132:261-269.
4. Cole JO, Gardos G. 1976. Psychopharmacology update. J McLean Hosp 1:155-165.
5. 1 agonism a prerequisite for mimicking clozapine's actions? Psychopharmacol DOI: 10.1007/s00213-004-2017-1 (online first).
6. Dekeyne A, Iob L, Millan MJ. 2003. Generalization of clozapine as compared to other antipsychotic agents to a discriminative stimulus elicited by the serotonin (5-HT)2A antagonist, MDL100,907. Neuropharmacology 44:604-615.
7. Extance K, Goudie AJ. 1981. Inter-animal olfactory cues in operant drug discrimination procedures in rats. Psychopharmacol 73:363-371.
8. Fiorella D, Helsley S, Rabin RA, Winter JC. 1997. Further investigations of the interactions of antipsychotics with the (-)2,5-dimethoxy-4- methylamphetamine (DOM) discriminative stimulus. Neuropharmacology 36:1463-1469.
9. Goas JA, Boston JE Jr. 1978. Discriminative stimulus properties of clozapine and chlorpromazine. Pharmacol Biochem Behav 8:235-241.
10. Goldstein A. 1964. Biostatistics: an introductory text. New York: MacMillan.
11. Goudie A, Taylor A. 1998. Comparative characterisation of the discriminative stimulus properties of clozapine and other antipsychotics in rats. Psychopharmacology 135:392-400.
12. Goudie AJ, Smith JA, Cole JC. 2004. Stimulus properties of the "atypical" antipsychotic zotepine in rats: comparisons with clozapine and quetiapine. Pharmacol Biochem Behav 77:163-173.
13. Goudie AJ, Smith JA, Taylor A, Taylor MA, Tricklebank MD. 1998. Discriminative stimulus properties of the atypical neuroleptic clozapine in rats: tests with subtype selective receptor ligands. Behav Pharmacol 9:699-710.
14. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY. 1993. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 34:702-712.
15. Herman E, Pleasure H. 1963. Clinical evaluation of thioridazine and chlorpromazine in chronic schizophrenics. Dis Nerv Syst 24:54-59.
16. Hoenicke EM, Vanecek SA, Woods JH. 1992. The discriminative stimulus effects of clozapine in pigeons: involvement of 5-hydrOxytryptamine1C and 5-hydroxytryptamine2 receptors. J Pharmacol Exp Ther 263:276-284.
17. Hyttel J, Larsen JJ, Christensen AV, Arnt J. 1985. Receptor-binding profiles of neuroleptics. Psychopharmacology Suppl 2:9-18.
18. Kane J, Honigfeld G, Singer J, Meltzer H. 1988. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796.
19. Kelley BM, Porter JH. 1997. The role of muscarinic cholinergic receptors in the discriminative stimulus properties of clozapine in rats. Pharmacol Biochem Behav 57:707-719.
20. Matz R, Rick W, Thompson H, Gershon S. 1974. Clozapine-a potential antipsychotic agent without extrapyramidal manifestations. Curr Ther Res Clin Exp 16:687-695.
21. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, and others. 2003b. Clozapine treatment for suicidality in schizophrenia; International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 60:82-91.
22. Meltzer HY, Fang VS. 1976. The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry 33:279-286.
23. Meltzer HY, Koenig JI, Nash JF, Gudelsky GA. 1989b. Melperone and clozapine: neuroendocrine effects of atypical neuroleptic drugs. Acta Psychiatr Scand Suppl 352:24-29.
24. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. 2003a. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27:1159-1172.
25. Meltzer HY, Matsubara S, Lee JC. 1989a. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251:238-246.
26. Meltzer HY, McGurk SR. 1999. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233-255.
27. Millan MJ, Schreiber R, Dekeyne A, Rivet JM, Bervoets K, Mavridis M, Sebban C, Maurel-Remy S, Newman-Tancredi A, Spedding M, and others. 1998. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo [1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin- 3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. J Pharmacol Exp Ther 286:1356-1373.
28. 1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. J Pharmacol Exp Ther 286:1356-1373.
29. Moore NA. 1999a. Olanzapine: preclinical pharmacology and recent findings. Br J Psychiatry Suppl 37:41-44.
30. Moore NA. 1999b. Behavioural pharmacology of the new generation of antipsychotic agents. Br J Psychiatry Suppl 38:5-11.
31. Moore NA, Tye NC, Axton MS, Risius FC. 1992. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 262:545-551.
32. Nielsen EB. 1988. Cholinergic mediation of the discriminative stimulus properties of clozapine. Psychopharmacology 94:115-118.
33. Philibin SD, Prus AJ, Pehrson AL, Porter JH. 2005. Serotonin receptor mechanisms mediate the discriminative stimulus properties of the atypical antipsychotic clozapine in C57BL/6 mice. Psychopharmacology. DOI: 10.1007/S00213-005-2147-0.
34. Porter JH, Covington HE, Varvel SA, Vann RE, Warren TA. 1998. Chlorpromazine as a discriminative stimulus in rats: generalization to typical and atypical antipsychotics. Drug Dev Res 48:38-44.
35. 2 dopamine receptors in the discriminative stimulus properties of the atypical antipsychotic clozapine in rats. Drug Dev Res 46:139-147.
36. Porter JH, Varvel SA, Vann RE, Philibin SD, Wise LE. 2000. Clozapine discrimination with a low training dose distinguishes atypical from typical antipsychotic drugs in rats. Psychopharmacology 149:189-193.
37. Porter JH, Prus AJ, Varvel SA, Vann RE. 2005. Discriminative stimulus properties of the atypical antipsychotic clozapine and the typical antipsychotic chlorpromazine in a three-choice drug discrimination procedure. Psychopharmacology 178:67-77.
38. Prus AJ, Baker LE, Meltzer HY. 2004. Discriminative stimulus properties of 1.25 mg/kg and 5.0 mg/kg doses of clozapine in rats: further examination of the role of dopamine, serotonin and muscarinic receptor mechanisms. Pharmacol Biochem Behav 77:199-208.
39. Prus AJ, Philibin SD, Pehrson AL, Cooper RN, Porter JH. Generalization to atypical antipsychotic drugs depends on training dose in rats trained to discriminate 1.25 mg/kg clozapine vs. 5.0 mg/kg clozapine vs. vehicle in a three-choice drug discrimination task. Behav Pharmacol. In press.
40. Richelson E, Souder T. 2000. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 68:29-39.
41. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE. 1996. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124:57-73.
42. Snyder SH, Greenberg D, Yamumura HI. 1974. Antischizophrenic drugs: affinity for muscarinic cholinergic receptor sites in the brain predicts extrapyramidal effects. J Psychiatr Res 11:91-95.
43. Stahl SM, Shayegan DK. 2003. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 64(suppl 19):6-12.
44. Stolerman IP, Mariathasan EA, White J-AW 1994. Implications of mixture research for discrimination of single drugs. Behav Pharmacol (suppl 5:18.
45. Stolerman IP, White J-AW, Mariathasan EA. 1996. Generalisations between mixtures of drugs under "AND" and "AND-OR" discrimination procedures in rats. In: Harris LS, editor. Problems of drug dependence. Washington, DC: US Government Printing Office, p 214.
46. Sur C, Mallorga PJ, Wittmann M, Jacobson MA, Pascarella D, Williams JB, Brandish PE, Pettibone DJ, Scolnick EM, Conn PJ. 2003. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci USA 100:13674-13679.
47. Tamminga CA. 1983. Atypical neuroleptics and novel antipsychotic drugs. In: Coyle JT, Enna SJ, editors. Neuroleptics: neurochemical, behavioral, and clinical perspectives. New York: Raven Press, pp 281-295.
48. Weiner DM, Meltzer HY, Veinbergs I, Donohue EM, Spalding TA, Smith TT, Mohell N, Harvey SC, Lameh J, Nash N, and others. 2004. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology 177:207-216.
49. Wiley JL, Porter JH. 1992. Serotonergic drugs do not substitute for clozapine in clozapine-trained rats in a two-lever drug discrimination procedure. Pharmacol Biochem Behav 43:961-965.
50. Young CR, Longhurst JG, Bowers MB Jr, Mazure CM. 1997. The expanding indications for clozapine. Exp Clin Psychopharmacol 5:216-234.